Top 5 Stocks to Buy Now
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel
NASDAQ:RKTO

Rocket One Inc. Common Stock Q2 2025 Earnings Report

Rocket One Inc. Common Stock logo
$1.08 0.00 (0.00%)
As of 06/18/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Rocket One Inc. Common Stock EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Rocket One Inc. Common Stock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rocket One Inc. Common Stock Announcement Details

Quarter
Q2 2025
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rocket One Inc. Common Stock's next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules.

Conference Call Resources

Rocket One Inc. Common Stock Earnings Headlines

Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
June 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rocket-one-reports-approximately-8-4-million-in-cash-and-cash-equivalents-and-outlines-strategy-across-ai-infrastructure-spintronic-computing-for-space-and-defense-markets-302800258.html
Space Stocks Get Torched: Short Seller Calls Them 'Sci-Fi Wishes'
June 12, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/06/53178299/space-stocks-get-torched-short-seller-calls-them-sci-fi-wishes?utm_source=snapi
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free.tc pixel
June 19 at 1:00 AM  |  Behind the Markets (Ad)
Rocket One (RKTO) stock is trending after hours as retired NASA astronaut joins advisory board: Here's what you need to know
June 12, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/rocket-one-rkto-stock-is-trending-after-hours-as-retired-nasa-astronaut-joins-advisory-board-here-s-what-you-need-to-know/ar-AA25rVpY
Zentalis Pharmaceuticals (NASDAQ:ZNTL) vs. Rocket One Inc. Common Stock (NASDAQ:RKTO) Head to Head Survey
June 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30834471
ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.
June 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rocket-one-appoints-major-general-malcolm-b-frost-ret-to-space-and-defense-advisory-board-302789753.html
See More Rocket One Inc. Common Stock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket One Inc. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket One Inc. Common Stock and other key companies, straight to your email.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis. The company holds exclusive worldwide licenses for a range of small molecules and biological compounds sourced from leading academic institutions and research organizations. By advancing these assets through preclinical studies and early-stage clinical trials, Hoth aims to validate therapeutic potential and move products toward regulatory milestones and eventual commercialization.

Founded in 2018 and headquartered in New York, Hoth Therapeutics operates through strategic collaborations with universities, entrepreneurial biotech firms and contract research organizations. The company’s management team brings expertise in drug development, regulatory affairs and commercial strategy, positioning Hoth to navigate the complexities of clinical advancement and market entry. With a focus on specialized delivery technologies and precision formulations, Hoth seeks to address unmet medical needs and deliver innovative treatment options to patients worldwide.

View Rocket One Inc. Common Stock Profile
Earnings Tools